Keywords: mylan, earnings, soar, fiscal, 2nd-qtr, strong, sales
Mylan's earnings soar 94% in fiscal 2nd-qtr
Article | 12 November 2007
Strong sales of products like the painkiller fentanyl, a copy-cat version of Johnson & Johnson's Duragesic, helped drive USA-based generics firm ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
